Join the B Cell Lymphoma group to help and get support from people like you.
B Cell Lymphoma News
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
WEDNESDAY, April 3, 2024 – Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a study published online March 19 in...
Liso-Cel Cost-Effective for Second-Line Relapsed/Refractory Lymphoma
THURSDAY, Jan. 4, 2024 – Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy,...
U.S. FDA Approves Label Update for Kite’s Yescarta CAR T-Cell Therapy to Include Overall Survival Data
Yescarta is the First and Only Treatment in Nearly 30 Years to Demonstrate Superior Overall Survival for Patients with Relapsed/Refractory Large B-cell Lymphoma Versus Standard of Care as...
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
TUESDAY, Dec. 12, 2023 – For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy...
FDA Approves Columvi (glofitamab-gxbm) Bispecific Antibody for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
South San Francisco, CA – June 15, 2023 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Columvi...
Many With Relapsed/Refractory Lymphoma in Pregnancy Delay Treatment
TUESDAY, June 6, 2023 – Most women with relapsed/refractory lymphoma during pregnancy defer therapy and there are few obstetric or neonatal complications, according to a study published online June...
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
In the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months...
FDA Approves Breyanzi (lisocabtagene maraleucel) CAR-T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE) February 5, 2021 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel;...
FDA Approves Keytruda (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
KENILWORTH, N.J.--(BUSINESS WIRE) June 13, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma
Basel, May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the ...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma